Ostarine (MK-2866, enobosarm) lowers testosterone, but in its trials the effect was mild at the doses tested. In older men and women taking 1 or 3 mg/day for 86 days, total testosterone in the men fell by 6.4 and 7.4 nmol/L compared with placebo, and SHBG fell on 3 mg; free testosterone, LH and FSH did not change significantly (Dalton 2011). A 14-day Phase 1 study in healthy men at up to 30 mg/day found dose-dependent drops in SHBG and total testosterone, without a clinically significant change in free testosterone (Phase 1 data, EMERALD protocol).

No study has followed recovery after ostarine or tested PCT after it. So the honest answer to “does ostarine need PCT?” is that it depends on dose and length, and only a blood test shows it. Below: PCT in short, the risks of PCT drugs, what ostarine is, the trial data, how to check, and the cycles people describe.

PCT, short summary

When androgens rise, the brain lowers LH and FSH, and the testes make less testosterone and sperm. Ostarine acts on the same androgen receptor, which is why total testosterone falls. PCT (post-cycle therapy) means drugs taken after a cycle to restart that chain: SERMs such as clomiphene and tamoxifen, sometimes hCG or an aromatase inhibitor. A 2026 review found the evidence for PCT limited and mostly observational, and noted that most users recover on their own (Smit 2026).

Older versions of this page said that after a cycle estrogen, progesterone and cortisol “spike” and the body turns catabolic. We could not find a study showing that for ostarine, so we removed it.

The danger of PCT

The drugs used for PCT have their own side effects, so using them without a reason has a cost:

Drug Main reported side effects
Clomiphene (Clomid) Visual symptoms that can be prolonged (the label says to stop and have the eyes checked), mood changes, breast tenderness, higher estradiol (label), (Krzastek 2019)
Tamoxifen (Nolvadex) Blood clots and stroke; loss of libido and impotence in men; liver enzyme changes (label)
Enclomiphene Headache, hot flushes, nausea, muscle spasm; four blood-clot events in trials (EMA 2018)

Two young men developed cholestatic liver injury after a few weeks of ligandrol and/or ostarine followed by post-cycle substances; the SARMs were the likely cause (Koller 2021).

What is ostarine, short summary

Ostarine (enobosarm, GTx-024) is the most-studied SARM. It reached Phase 3: two lung cancer trials (POWER 1 and 2) missed their main endpoints in 2014 (GTx 2014). In the Phase 2 trial in older adults, 3 mg/day raised lean mass by 1.3 kg more than placebo over 86 days and improved physical function; HDL fell 17% on 1 mg and 27% on 3 mg (Dalton 2011). It has never been approved, and WADA bans it at all times.

Older versions of this page claimed an 8-week cycle typically brings 3–5% body-fat loss and about five pounds of muscle. No study supports those figures. Side effects with evidence behind them: lower total testosterone and SHBG, lower HDL, raised liver enzymes (dose-dependent in the Phase 1 study), and case reports of cholestatic liver injury in young men using ostarine products (2024). Full profile: Ostarine (MK-2866) review.

Does ostarine need a PCT?

What the trials show:

  • Total testosterone falls; free testosterone held at 1–3 mg/day. In older men, total testosterone dropped about 6–7 nmol/L vs placebo while free testosterone, LH and FSH did not change significantly (Dalton 2011). Part of the fall in total testosterone comes from lower SHBG, the protein that carries it.
  • Higher doses push harder. Up to 30 mg/day for 14 days lowered SHBG and total testosterone with dose (Phase 1 data).
  • Recovery has not been measured after ostarine, and no PCT has been tested after it.

On our 0–3 scale ostarine scores 2 (moderate). For comparison, LGD 4033 scores 3: see SARMs PCT and ostarine suppression.

What do the studies say?

People often point to the trials and say participants needed no PCT. That is true, but most trials used 0.1–3 mg/day for up to about five months (9–18 mg/day in women with breast cancer), and they did not report recovery after stopping. Cycles described online, including older versions of this page, use 10–25 mg/day. The table lists what was actually tested:

Dose Who How long Hormone and safety findings
0.1–3 mg/day Healthy men over 60 and postmenopausal women 86 days Total testosterone and SHBG down; free testosterone, LH, FSH unchanged; HDL down 17–27% (Dalton 2011)
1 or 3 mg/day Adults with cancer and weight loss Up to 113 days Lean mass up 1.0–1.5 kg; serious adverse events not judged drug-related (Dobs 2013)
1, 3, 10 or 30 mg/day Healthy young men and older men (Phase 1) 14 days SHBG and total testosterone down with dose; ALT rise was the most common side effect (Phase 1 data)
9 or 18 mg/day Women with advanced breast cancer Until progression Grade 3/4 drug-related side effects in 8% and 16%, most often raised liver enzymes (Palmieri 2024)

How to know if you need a PCT

A blood test, after ostarine has cleared. Ostarine’s half-life is about 14–24 hours (Phase 1 data); after five half-lives about 3% is left (StatPearls), so about 3–5 days after the last dose.

  • Total testosterone, fasting and in the morning, repeated if low (Bhasin 2018).
  • Free testosterone and SHBG. Because ostarine lowers SHBG, total testosterone can look low while free testosterone is normal; the guideline recommends free testosterone when SHBG is altered (Bhasin 2018).
  • LH and FSH, to see whether the brain’s signal is switched down.
  • HDL, ALT/AST and bilirubin, which changed in the ostarine trials and case reports.

A test before the cycle makes the after-test meaningful. Ranges and meaning: SARMs bloodwork. Timeline for your stack: PCT & Bloodwork Planner.

No PCT ostarine cycle examples

Older versions of this page listed three “no PCT” ostarine cycles from personal use: about 15 mg/day (bulking), 10 mg/day (cutting) and 20 mg/day (recomp), each for eight weeks. These are user reports, not tested regimens. Compared with the trials:

Cycle described (anecdotal) Closest studied dose What is known
10 mg/day, 8 weeks 10 mg/day for 14 days (Phase 1) SHBG and total testosterone fell with dose; recovery not reported (Phase 1 data)
15–20 mg/day, 8 weeks 9–18 mg/day in women with breast cancer; 30 mg/day for 14 days in men Liver-enzyme rises were the most common serious side effect at 9–18 mg/day (Palmieri 2024); no data on male hormones over 8 weeks

No study shows that any of these cycles avoids suppression or that recovery after them is complete.

PCT after ostarine: what has been studied

Older versions of this page recommended a four-week Nolvadex course, with a higher start above 25 mg/day of ostarine. No study has tested that, or any PCT after ostarine. What exists:

  • Tamoxifen raised testosterone about 40% and LH about 70% in healthy men over two weeks (Birzniece 2010). Not tested after SARMs. Nolvadex PCT.
  • Clomiphene sped up hormone recovery after up to 6 months of steroids in an observational study, though untreated men also normalized by month 6 (İbis 2026). Clomid PCT.
  • Enclomiphene raised testosterone and kept sperm counts in men with secondary hypogonadism (Kim 2016). Not tested after SARMs. Enclomiphene.

Ostarine under 25 mg a day

The male trials used up to 3 mg/day for months and up to 30 mg/day for two weeks. Free testosterone, LH and FSH held at 1–3 mg/day (Dalton 2011). Whether that holds at 10–20 mg/day for eight weeks is unknown, which is why a blood test after the cycle is the deciding factor.

Ostarine over 25 mg a day

Only the 14-day Phase 1 study went this high (30 mg/day), and total testosterone and SHBG fell with dose (Phase 1 data). Liver-enzyme rises were dose-dependent in the same study, and liver injury is the most serious risk in the case reports (2024). At these doses, liver enzymes and bilirubin belong in the blood test too.

Conclusion

Ostarine lowers total testosterone and SHBG at every dose tested, while free testosterone, LH and FSH held at the low trial doses. Nobody has measured recovery after an ostarine cycle or tested PCT after one. A blood test before and after the cycle, once ostarine has cleared, is how to know. Related: ostarine dosage, ostarine cycle length, ostarine before and after.

Frequently asked questions

Does ostarine need a PCT?

Unknown; never testedEvidence: Trial

In older men, 1–3 mg/day lowered total testosterone by about 6–7 nmol/L vs placebo, while free testosterone, LH and FSH did not change significantly. Higher doses, longer cycles and recovery have not been studied.

Read the full section

How suppressive is ostarine?

Moderate (2 of 3)Evidence: Trial

Total testosterone and SHBG fell in every trial that measured them; at 1–3 mg/day, free testosterone, LH and FSH held. LGD-4033 suppressed more at lower doses.

Read the full section

Is ostarine suppressive at low doses?

Yes, for total testosteroneEvidence: Trial

Total testosterone and SHBG fell in older men at 1 and 3 mg/day over 86 days. Free testosterone did not change significantly at those doses.

Read the full section

What is the best PCT for ostarine?

None tested after ostarineEvidence: Limited

Tamoxifen and enclomiphene raise testosterone in men, and clomiphene sped up recovery after steroids in an observational study. Each has its own risks, such as blood clots (tamoxifen, enclomiphene) and visual symptoms (clomiphene).

Read the full section

How long after ostarine should bloodwork be done?

About 3–5 days afterEvidence: Human data

Ostarine's half-life is about 14–24 hours, so about 97% is cleared 3–5 days after the last dose. The trials tracked total and free testosterone, SHBG, LH, FSH, HDL, liver enzymes and bilirubin.

Read the full section

Do you need PCT for ostarine at 10 mg a day?

UnknownEvidence: Trial

10 mg/day was only tested for 14 days in a Phase 1 study, where total testosterone and SHBG fell with dose. An 8-week course at that dose has not been studied.

Read the full section

Sources

  1. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial 2011 · PMID 22031847
  2. EMERALD study protocol (ISRCTN12213700, University of Liverpool, version 6.0, 2021): a window of opportunity study of enobosarm in ER+/AR+ early breast cancer 2021
  3. Post-cycle therapy after androgen abuse: a narrative review of mechanisms, evidence, and clinical perspectives 2026 · PMID 42644333
  4. CLOMID (clomiphene citrate) tablets – prescribing information (DailyMed) 2025
  5. Long-Term Safety and Efficacy of Clomiphene Citrate for the Treatment of Hypogonadism 2019 · PMID 31216250
  6. Tamoxifen citrate tablets – prescribing information (DailyMed, Mylan) 2026
  7. EnCyzix (enclomifene): public assessment report, EMA/88321/2018 2018
  8. Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature review 2021 · PMID 34141767
  9. GTx, Inc. Provides Corporate Update And Reports 2013 Financial Results (press release, 4 March 2014) 2014
  10. Liver Injury after Selective Androgen Receptor Modulator Intake: A Case Report and Review of the Literature 2024 · PMID 37871633
  11. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial 2013 · PMID 23499390
  12. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial 2024 · PMID 38342115
  13. Elimination Half-Life of Drugs (StatPearls, NCBI Bookshelf) 2025 · PMID 32119385
  14. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline 2018 · PMID 29562364
  15. Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men 2010 · PMID 20843951
  16. Post-cycle therapy after short-term anabolic-androgenic steroid use: comparative outcomes in recreational bodybuilders 2026 · PMID 41147237
  17. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement 2016 · PMID 26496621